BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Zalicus Inc. 

245 First Street
Third Floor
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-301-7000 Fax: 617-301-7010


View Clinical Trials from BioPharm Insight

Zalicus (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain and immuno-inflammatory diseases and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective Ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit Zalicus is a public company with 40 employees.

 Key Statistics

Ownership: Public

Web Site: Zalicus Inc.
Employees: 102
Symbol: ZLCS

 Company News
EPIRUS Biopharmaceuticals And Zalicus Inc. (ZLCS) Complete Merger - Combined Company Will Trade As EPIRUS Biopharmaceuticals 7/15/2014 10:46:32 AM
Zalicus Inc. (ZLCS) And EPIRUS Biopharmaceuticals Agree Zalicus Stockholders To Own 19 Percent Of Combined Company Post-Merger 6/25/2014 8:59:00 AM
Zalicus Inc. (ZLCS) Licenses Sodium Channel Pain Modulation Program 6/18/2014 10:12:37 AM
Zalicus Inc. (ZLCS) Announces Closing Of CHTS Service Business Sale To Horizon Discovery Group 6/2/2014 10:32:34 AM
Zalicus Inc. (ZLCS) Updates Progress On Z944 Clinical Development 5/22/2014 9:47:33 AM
Zalicus Inc. (ZLCS) Reports Financial Results For The First Quarter 2014 5/9/2014 7:47:18 AM
Boston-Based EPIRUS Biopharmaceuticals Reels In $36 Million Series B, Will Merge With Zalicus Inc. (ZLCS) In All-Stock Deal 4/16/2014 6:31:56 AM
Zalicus Inc. (ZLCS)To Present At American Association for Cancer Research 2014 Annual Meeting 4/1/2014 7:22:31 AM
Zalicus Inc. (ZLCS) Reports Financial Results For The Fourth Quarter And Year-End 2013 3/13/2014 6:53:23 AM
Zalicus Inc. (ZLCS) Drops Pain Drug After Phase 2 Clinical Trials Fail; Stock Plumments -71.60% at 10:12AM ET on Monday 11/11/2013 7:40:33 AM